WEBINAR DESCRIPTION
Webinar Description
Two main ways lead to drug discovery:
the persistent lab work, which includes inspirational incidents,
and/or
the out of the box thinking. This inventive add has to be imported by pharma labs, being a must in drugs discovery today, when interdisciplinarity is an asset.
The webinar is the expression of scientific freedom and interdisciplinary education.
The neurotoxicity is a problem to handle in a better way. Firstly, because brain health is mandatory in postmodern tech civilization. The increase of mental health issues in all ages with respect to decades ago, is a complex question, pushing to wider inference of view points in neuroscience.
Also, because the huge amount of open knowledge stored in digital libraries is challenging the scientific work, uprising unexpected shortcuts.
Following an old but incompletely explored concept of intact and sliced brain, introduced by Mircea Steriade in late ninties, the webinar gives innovative insides about synergistic ways to handle neurotoxicity. Caring about the logical understanding of delivered plus value, the topic is structured in 5 chapters:
I.Observational Investigation: where to look for data and how to interpret them.
A. Classification criteria and examples
of neurotoxicity
B. Neurotoxicity as side effect
II. Explanatory Models: patients are different one from another
III. Functional Observations: mathematics everywhere.
IV. Categories of new drugs which may help reduce neurotoxicity: the currency word is 'systemic'!
V. Pharma Lab - fostering personalized medicine in AI era:roadmaps to successfully handle neurotoxicity by procedural drugs discovery.
KEYNOTER
Dr. Adriana Climescu-Haulica is a mathematician known for her non standard approach in life sciences. Her doctoral work was acknowledged as the best thesis of the year of Mathematics Departement at Federal Polytehnic School of Lausanne (EPFL) in 1999. The subject, 'Stochastic Calculus for Random Signals Detection' is still actual, and opens to interdisciplinary research. She started her carrier as scientist for Communication Research Centre in Ottawa, applying her fundamental work to Signal Processing and Information Theory, while learning Wireless Communication.
Her interest in Neuroscience started in 2004 while teaching a Machine Laerning course to ENSIMAG students from National Polytechnic Institute in Grenoble. She was curios to understand the physiological neuron and spike time plasticity. Participating to a prestigious conference in Neuroscience with a work about theoretical modeling of learning in spikes environment she noticed the real interpretability of the data measurements is sparse, and she got persuaded the field has to wait for more precise tools. Paying attention to understand the hidden part of talks, she was impressed about the dependence of brain functioning on molecular mechanisms. Hence, her next step was to integrate as scientist the best Bioinformatics CNRS lab, Information Genomique et Structurale in Marseille, directed by Prof. Jean-Michel Claverie, where she participated to a Sanofi project on identifying leads for oncology. From now on, her main interest was personalized medicine. In 2011 she initiates a comprehensive project on neuro-endocrinology, sought as fundamental milestone for systemic molecular medicine. For 10 years she was the President and Director R&D of Bioclinome, an innovative french startup whose ambition, ahead of time, was to introduce large scale personalized medicine. Due to the progress on monitoring local accuracy of electrical brain activity, the time has come to present original findings on Neuroscience to interested scientists and healthcare practitioners, letting them make benefit of it. Specific work will be pursued by Avantiv team in collaborative forms, the webinar is a first step to establish joint work.
Since 2021 Adriana is Director of Avantiv Limited, company situated in Cambridge UK, she funded to proliferate mathematically rigorous methods in science, focusing on challenging the robotic approach of today Machine Learning and AI. She is contributor for more than 30 peer review publications, half of them as single author. She was awarded two innovation prizes from the French gouvernment.